- Home
- JYNT vs OBIO Comparison
JYNT vs OBIO Comparison
Compare JYNT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- OBIO
- Stock Information
- Founded
- JYNT 2010
- OBIO 2017
- Country
- JYNT United States
- OBIO United States
- Employees
- JYNT N/A
- OBIO N/A
- Industry
- JYNT Multi-Sector Companies
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- JYNT Miscellaneous
- OBIO Health Care
- Exchange
- JYNT Nasdaq
- OBIO Nasdaq
- Market Cap
- JYNT 149.5M
- OBIO 172.1M
- IPO Year
- JYNT 2014
- OBIO N/A
- Fundamental
- Price
- JYNT $8.23
- OBIO $3.32
- Analyst Decision
- JYNT Strong Buy
- OBIO Strong Buy
- Analyst Count
- JYNT 3
- OBIO 4
- Target Price
- JYNT $16.33
- OBIO $14.00
- AVG Volume (30 Days)
- JYNT 103.8K
- OBIO 341.9K
- Earning Date
- JYNT 11-06-2025
- OBIO 11-11-2025
- Dividend Yield
- JYNT N/A
- OBIO N/A
- EPS Growth
- JYNT N/A
- OBIO N/A
- EPS
- JYNT N/A
- OBIO N/A
- Revenue
- JYNT $53,449,713.00
- OBIO $2,944,000.00
- Revenue This Year
- JYNT $7.70
- OBIO $29.26
- Revenue Next Year
- JYNT $10.24
- OBIO $10.65
- P/E Ratio
- JYNT N/A
- OBIO N/A
- Revenue Growth
- JYNT 277.36
- OBIO 41.61
- 52 Week Low
- JYNT $8.01
- OBIO $2.20
- 52 Week High
- JYNT $13.47
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- JYNT 26.97
- OBIO 63.60
- Support Level
- JYNT $8.16
- OBIO $2.66
- Resistance Level
- JYNT $8.60
- OBIO $3.80
- Average True Range (ATR)
- JYNT 0.33
- OBIO 0.26
- MACD
- JYNT -0.04
- OBIO 0.10
- Stochastic Oscillator
- JYNT 12.39
- OBIO 67.14
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.